Poster

A first-in-human phase 1/2 study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Author

Timothy A. Yap

Condition

advanced solid tumors

Drug target

CDK2

Drug moa

CDK2 inhibition

Source url

s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-ESMO-2022-BLU-222-VELA-Trial-Poster.pdf

6 organizations

1 product

Product

Organization

Organization